GlassScriptPhysician profile
Katherine J Atkinson
NPI 1700849643
$6,097.54
in general payments reported to CMS, 2019-2025
41 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,223 · 2020: $871 · 2021: $361 · 2022: $560 · 2023: $1,031 · 2024: $449 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,186.33 | 2019-2024 | Spravato |
| Surgi-Care, INC. | $780.00 | 2019 | |
| Pfizer INC. | $458.99 | 2019-2024 | |
| Glaxosmithkline, LLC. | $398.61 | 2019-2023 | Bexsero, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $354.52 | 2019-2025 | Airsupra |
| Astellas Pharma US INC | $301.42 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $270.75 | 2019-2025 | Kisunla |
| Ironshore Pharmaceuticals INC. | $232.43 | 2019 | |
| Amgen INC. | $184.71 | 2019-2025 | Evenity |
| Abbvie INC. | $184.10 | 2022-2025 | Qulipta, Vraylar |
| Myriad Women'S Health, INC. | $165.59 | 2023 | Myrisk |
| E.R. Squibb & Sons, L.L.C. | $160.60 | 2019-2025 | Camzyos, Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $150.22 | 2022 | |
| Merck Sharp & Dohme LLC | $146.39 | 2019-2024 | M-M-R II, Gardasil 9, Vaxelis |
| Paragonix Technologies, INC. | $124.10 | 2025 | Baroguard |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $106.61 | 2020-2023 | Rexulti |
| Sanofi Pasteur INC. | $90.65 | 2021-2023 | |
| Novo Nordisk INC | $89.85 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Radius Health, INC. | $79.19 | 2023-2025 | Tymlos |
| Allergan, INC. | $73.43 | 2020-2021 | |
| Therapeuticsmd, INC. | $67.46 | 2019-2020 | |
| Abbott Laboratories | $46.01 | 2022-2023 | Freestyle Libre 3 |
| Indivior INC. | $39.97 | 2022-2025 | Sublocade |
| Biohaven Pharmaceuticals, INC. | $35.94 | 2021 | |
| Alkermes, INC. | $33.93 | 2021-2024 | Vivitrol |
| Bayer Healthcare Pharmaceuticals INC. | $33.85 | 2025 | |
| Exact Sciences Corporation | $33.44 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $28.97 | 2023 | |
| Genzyme Corporation | $26.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.24 | 2019 | |
| Exeltis, USA INC. | $23.52 | 2024 | Slynd |
| Tolmar, INC. | $22.35 | 2025 | Fensolvi |
| Braeburn INC. | $21.06 | 2023 | Brixadi |
| Ibsa Pharma INC. | $20.97 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.09 | 2021 | |
| Echosens North America, INC. | $16.84 | 2025 | Fibroscan |
| Amarin Pharma, INC. | $14.47 | 2020 | |
| Redhill Biopharma INC. | $13.83 | 2020 | |
| Organon LLC | $12.91 | 2025 | Nexplanon |
| Seqirus USA INC | $12.81 | 2020 | |
| Titan Pharmaceuticals, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.